3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Breast Neoplasms
12
Pancreatic Neoplasms
6
Neoplasms
6
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Leukemia, Myeloid, Acute
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Multiple Myeloma
4
Lung Neoplasms
4
Leukemia
4
Colorectal Neoplasms
4
Recurrence
3
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Radiodermatitis
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Melanoma
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Communication
2
Carcinoma, Transitional Cell
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Interventions
Cyclophosphamide
130
Methotrexate
93
fludarabine phosphate
74
Cytarabine
71
Vincristine
66
Whole-Body Irradiation
65
Mycophenolic Acid
58
Dexamethasone
55
Tacrolimus
49
Peripheral Blood Stem Cell Transplantation
48
fludarabine
47
Busulfan
46
pegaspargase
43
Filgrastim
41
Etoposide
41
Doxorubicin
41
Calcium Dobesilate
40
Granulocyte Colony-Stimulating Factor
39
Rituximab
36
Cyclosporine
36
Mercaptopurine
35
Melphalan
33
Prednisone
31
merphos
28
Clofarabine
26
Asparaginase
26
Antilymphocyte Serum
25
Leucovorin
23
Daunorubicin
23
Thiotepa
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Standard of Care
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts